Barclays (LON:BARC) analyst Carter Gould maintained a Buy rating on Alector (NASDAQ:ALEC) Inc on Monday, setting a price target of $42, which is approximately 34.19% above the present share price of $31.3.
Gould expects Alector Inc to post earnings per share (EPS) of -$0.66 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Alector, with an average price target of $39.4.
The analysts price targets range from a high of $57 to a low of $28.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $4.11 million and a net profit of -$52.64 million. The company's market cap is $2.5 billion.
According to TipRanks.com, Barclays analyst Carter Gould is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.8% and a 44.74% success rate.
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.